The ONE ABBOTT SOLUTION FOR
ID NOW COVID-19 TESTING
The One Abbott Solution1 for ID NOW COVID-19 testing is a simple, reliable and secure end-to-end connectivity and reporting solution. It offers speed and performance for ID NOW™2 COVID-19 testing and reporting within 24 hours3 for decentralized environments to help you manage data without infrastructure burden.
Download brochure Testing and Reporting Customer Workflow video (2:25 min)
Testing patients at the point of care
The ID NOW™ platform, the most widely-used point-of-care molecular device for COVID-19 detection provides results in 13 minutes or less. It is also portable and allows use in any patient care setting, including decentralized locations.
Capturing results without manual entry
RALS™ LiNK connectivity tracks, captures and consolidates patient results from multiple ID NOW™ instruments and sends data to the STARLIMS Digital Solution with no manual entry. It also provides customizable dashboards which give you access to ID NOW™ COVID-19 testing data and analytics.
Capturing and reporting demographics in near real time
STARLIMS Digital Solution collects ordering physician data, patient questions and test results for ID NOW™ COVID-19 testing, and reports this data accurately to public health local and federal authorities within 24 hours. It also supports Influenza A & B reporting for New York.
Learn more about Abbott's ID Now.
Learn more about Abbott's RALS LiNK.
Listen to a timely educational webinar on the CARES Act, information gathering, and test reporting for COVID-19 testing sites.
1Only available in the US. 2The ID NOW™ COVID-19 EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories and patient care settings. The test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. 3Reporting services may not be available in certain States.
